Chronic primary mitral regurgitation (MR)
Valvular heart disease · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Systolic backflow into the LA from a degenerative/primary valve problem (prolapse, flail, chordal rupture) causing LV and LA volume overload. Distinguish primary (valve) from secondary/functional MR (ventricular). Durable mitral repair is the goal in severe primary MR.
Red flags
- New or worsening dyspnoea / reduced exercise tolerance
- Falling LVEF toward 60% or LVESD approaching 40 mm (primary MR)
- New AF or pulmonary hypertension
- Acute severe MR — flash pulmonary oedema, hypotension (papillary rupture/endocarditis) = emergency
- Fever + new murmur (endocarditis)
Assessment
Differential diagnosis
- Secondary/functional MR (LV dilatation/ischaemia)
- Acute MR (papillary muscle rupture, endocarditis) — emergency
- Tricuspid regurgitation
- Ventricular septal defect
- Hypertrophic obstructive cardiomyopathy with SAM
Investigations
- Echocardiogram (TTE +/- TOE) — mechanism, severity (regurgitant volume/fraction, EROA), LV size/EF, LA size, PA pressure
- ECG (AF, LVH), CXR
- Exercise echo if symptoms/severity discordant
- Cardiac MRI for quantification when echo equivocal
- BNP/NT-proBNP; coronary angiography before surgery
Management
- Define mechanism (primary vs secondary) and grade severity
- Track LV end-systolic diameter and LVEF — intervention triggers in primary severe MR: symptoms, or asymptomatic with LVEF <=60% or LVESD >=40 mm
- Refer early to a Heart Team / mitral specialist centre — repair (not replacement) is preferred for degenerative MR when feasibility is high
- Manage AF (rate/rhythm + anticoagulation) and treat congestion
- For secondary MR: optimise HFrEF GDMT first; consider transcatheter edge-to-edge repair (TEER/MitraClip) in selected symptomatic patients on optimal therapy (COAPT)
- Surveillance echo 6-12 monthly in severe asymptomatic MR
Drugs & doses
No proven medical therapy slows primary MR — intervention is definitive
For secondary MR: full HFrEF GDMT (ARNI/ACEi, beta-blocker, MRA, SGLT2i — see HFrEF entry)
Furosemide 20-40 mg PO once/twice daily for congestion
Rate control / anticoagulation for AF: bisoprolol + apixaban 5 mg PO BD (dose-adjust)
Treat hypertension (afterload reduction) with ACEi/ARB in symptomatic patients [verify]
Disposition
Outpatient surveillance and early Heart Team referral for severe MR; admit acute MR/decompensation urgently.
Complications & pitfalls
- Progressive LV dysfunction and heart failure
- Atrial fibrillation
- Pulmonary hypertension / right heart failure
- Infective endocarditis
- Sudden death (flail leaflet, severe MR)
Exam pearls
- In primary severe MR, intervene BEFORE LVEF falls below 60% or LVESD reaches 40 mm — a 'normal' LVEF of 60% is already impaired in volume-overloaded MR (2020 AHA/ACC, 2021 ESC).
- Degenerative MR: mitral REPAIR at an experienced centre has far better outcomes than replacement — refer early.
- Secondary MR is a ventricular disease — treat the HF first; TEER (COAPT) benefits a selected group with proportionate MR on optimal GDMT.
- Acute severe MR presents as flash pulmonary oedema with a soft/absent murmur — do not be reassured by the exam.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.